Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Annu Rev Med. 2010;61:153. doi: 10.1146/annurev.med.042508.093728

Table 1. HIV-1 vaccine efficacy studies.

Vaccine Concept Developer Study Status
1. monomeric gp120 (B/B, B/E) VaxGen VAX 003, VAX 004 (phase 3) completed in 2003 (42, 43)
2. rAd5-Gag/Pol/Nef Merck HVTN 502 “STEP” (phase 2b) stopped in 2007 (49)
3. ALVAC (vCP1521) prime, gp120 (B/E) boost Sanofi, VaxGen RV 144 (phase 3) will be completed in 2009
4. DNA prime, rAd5 boost Gag/Pol/EnvA/EnvB/EnvC NIH VRC HVTN 505 (phase 2) scheduled to begin in 2009